ventolin nebules 2.5mg solution for inhalation
glaxosmithkline (ireland) limited (0000010774) 12 riverwalk, citywest business campus, dublin, dublin 24 - salbutamol sulfate - solution for inhalation - 2.5mg - salbutamol sulfate (0051022709) 3mg - salbutamol
cataflam 50mg tablet, coated
novartis ireland limited (0000010772) vista building, elm park, merrion road, ballsbridge, dublin, dublin 4 - diclofenac potassium - tablet, coated - 50mg - diclofenac potassium (8000001048) 50mg - diclofenac
ventolin diskus 200mcg powder for inhalation
glaxosmithkline (ireland) limited (0000010774) 12 riverwalk, citywest business campus, dublin, dublin 24 - salbutamol sulfate - powder for inhalation - 200mcg - salbutamol sulfate (0051022709) 200mcg base - salbutamol
ventolin evohaler 100mcg/dose aerosol
glaxosmithkline (ireland) limited (0000010774) 12 riverwalk, citywest business campus, dublin, dublin 24 - salbutamol - aerosol - 100mcg/dose - salbutamol (0018559949) 100ug - salbutamol
vazkepa
amarin pharmaceuticals ireland limited - icosapent ethyl - Δυσλιπιδαιμίες - Παράγοντες τροποποίησης λιπιδίων - indicated to reduce cardiovascular risk as an adjunct to statin therapy.
lamisil 125mg tablets
novartis ireland limited (0000010772) vista building, elm park, merrion road, ballsbridge, dublin, dublin 4 - terbinafine hydrochloride - tablets - 125mg - terbinafine hydrochloride (8000001212) 140,625mg - terbinafine
lamisil 250mg tablets
novartis ireland limited (0000010772) vista building, elm park, merrion road, ballsbridge, dublin, dublin 4 - terbinafine hydrochloride - tablets - 250mg - terbinafine hydrochloride (8000001212) 281,25mg - terbinafine
ventolin 2mg/5ml σιροπι
glaxosmithkline (ireland) limited (0000010774) 12 riverwalk, citywest business campus, dublin, dublin 24 - salbutamol sulfate - ΣΙΡΟΠΙ - 2mg/5ml - salbutamol sulfate (0051022709) 2,4mg - salbutamol
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. θεραπεία τριπλού συνδυασμού) ως επιπρόσθετο στη δίαιτα και την άσκηση σε ασθενείς που δεν ελέγχονται επαρκώς με μέγιστη ανεκτή για αυτούς δόση μετφορμίνης και σουλφονυλουρίας. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - υδροχλωρική κλοπιδογρέλη - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - Αντιθρομβωτικοί παράγοντες - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.